NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

5914.50 -217.00 (-3.54%)

28.14% Gain from 52W Low

553.6K NSE+BSE Volume

NSE 08 Aug, 2025 3:31 PM (IST)

157,011.4

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Estimates Miss

Divi's Lab's Q1FY26 profit rises 26.7% YoY, but misses Forecaster estimates by 7.7% See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

10 Aug 2015

5914.50

-3.54%

DivisLab 10Aug2015

Neutral: Divi's Laboratories Ltd.

Phillip Capital

Divi's Q1FY16 operating performance was just in line with our estimates with 26%/32% growth in sales/adjusted profit. Going ahead, the management expects to maintainsteadygrowthledbyprocessimprovementintheexistinggenericmolecules...

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.

Divi's Laboratories Ltd.

10 Aug 2015

5914.50

-3.54%

Divis Laboratories - 1QFY16 Result Update

Hold: Divi's Laboratories Ltd.

Reliance Securities

ff Divi's has reiterated its sales guidance at 15-20% and 37-38% margins for FY16E. Any new launches or approvals will add incrementally to the growth. Revenues of Nutraceuticals are guided at Rs2.2bn in FY16E, implying traction ahead. ff DSN SEZ contributed Rs2bn in 1Q as capacity utilization scaled up at 90%+,...

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.

Divi's Laboratories Ltd.

26 May 2015

5914.50

-3.54%

DivisLab 26May2015

Neutral: Divi's Laboratories Ltd.

Phillip Capital

finetuned our FY16/FY17 EPS estimates to Rs 77.8/92.4, 2.9%/2.4% higher than before. We now value the company at Rs 1,940, 21x FY17 EPS, vs. Rs 1,900 earlier. Due to the limited upside potential (5%), we retain our NEUTRAL rating. The company's 80%+...

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

25 May 2015

5914.50

-3.54%

Divis Laboratories: Q4FY15 Result Review-Better gross margins aid margins (May 25, 2015)

Hold: Divi's Laboratories Ltd.

Karvy

Divi's Lab Total revenues are up by 10.3% YoY to Rs 8.2 bn lower than our expectation of Rs 8.8 bn during the quarter. Operating margins stood at 38.6% higher than our estimate of 34.9% on account of lower raw material cost.

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

02 Feb 2015

5914.50

-3.54%

Divis Laboratories Ltd: Result Review (Feb 02, 2015)

Buy: Divi's Laboratories Ltd.

Karvy

Divis Labs Total revenues are up by 14.8% YoY to Rs7.9 bn against our expectation of Rs8.3 bn during the quarter. Operating margins were at 36.3% lower than our estimate of 39.3% due to higher raw material, staff and other cost. Net Profit was up by 0.7% to Rs2,206 mn ( lower than our estimates of Rs2,420 mn)

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.

Divi's Laboratories Ltd.

04 Jun 2013

5914.50

-3.54%

Divis Laboratories Limited

Buy: Divi's Laboratories Ltd.

Ashika Research

Divi's is well-positioned in the Contract/Custom Research and Manufacturing Services (CRAMS) space, given its strong relationships with innovators, thus with presence...

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf